CN114470312B - Non-leakage packaged yeast hydrogel and preparation method thereof - Google Patents
Non-leakage packaged yeast hydrogel and preparation method thereof Download PDFInfo
- Publication number
- CN114470312B CN114470312B CN202210103555.3A CN202210103555A CN114470312B CN 114470312 B CN114470312 B CN 114470312B CN 202210103555 A CN202210103555 A CN 202210103555A CN 114470312 B CN114470312 B CN 114470312B
- Authority
- CN
- China
- Prior art keywords
- yeast
- hydrogel
- suspension
- engineering
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 140
- 239000000017 hydrogel Substances 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 241000894006 Bacteria Species 0.000 claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 238000004132 cross linking Methods 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 230000003647 oxidation Effects 0.000 claims abstract description 17
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 17
- 238000011065 in-situ storage Methods 0.000 claims abstract description 13
- 229920002521 macromolecule Polymers 0.000 claims abstract description 13
- 235000000346 sugar Nutrition 0.000 claims abstract description 13
- 230000000977 initiatory effect Effects 0.000 claims abstract description 10
- 239000000725 suspension Substances 0.000 claims description 66
- 239000008055 phosphate buffer solution Substances 0.000 claims description 36
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical group [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 30
- 239000007853 buffer solution Substances 0.000 claims description 29
- 210000005253 yeast cell Anatomy 0.000 claims description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 239000003102 growth factor Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 18
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 16
- 229920002674 hyaluronan Polymers 0.000 claims description 15
- 229960003160 hyaluronic acid Drugs 0.000 claims description 15
- 229940116978 human epidermal growth factor Drugs 0.000 claims description 14
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 11
- 239000003999 initiator Substances 0.000 claims description 11
- 239000007800 oxidant agent Substances 0.000 claims description 11
- 229960005070 ascorbic acid Drugs 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 10
- 239000011668 ascorbic acid Substances 0.000 claims description 10
- 230000001590 oxidative effect Effects 0.000 claims description 10
- CYUOIOGMTVJOAB-UHFFFAOYSA-N 2-aminooxyethyl 2-bromo-2-methylpropanoate Chemical group CC(C)(Br)C(=O)OCCON CYUOIOGMTVJOAB-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 8
- 235000015110 jellies Nutrition 0.000 claims description 8
- 239000008274 jelly Substances 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- -1 cuBr Substances 0.000 claims description 7
- 230000001678 irradiating effect Effects 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical group FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 102000058223 human VEGFA Human genes 0.000 claims description 2
- 238000009630 liquid culture Methods 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 239000004971 Cross linker Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 abstract description 2
- 230000028993 immune response Effects 0.000 abstract 1
- 241000872931 Myoporum sandwicense Species 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 238000010276 construction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical group CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a leak-free encapsulated yeast hydrogel and a preparation method thereof. The leakage-free encapsulated yeast hydrogel is prepared by constructing yeast engineering bacteria carrying human genes, carrying out in-situ oxidation on sugar chains on the surfaces of the obtained engineering yeast, initiating and carrying out specific crosslinking on macromolecules. The hydrogel can prevent leakage of yeast, reduce possible immune response when directly contacting human body, and accelerate wound healing. The invention has the advantages that: good biocompatibility, mild reaction and wide application prospect.
Description
Technical Field
The invention belongs to the field of biomedicine, and particularly relates to a leak-free packaged yeast hydrogel and a preparation method thereof.
Background
In past studies, the use of conventional dressings such as medical absorbent cotton gauze has not been satisfactory. The liquid absorption amount is not large enough and needs to be replaced frequently. After imbibing, the dressing is easy to dry and easy to adhere to wounds to cause secondary wounds, so the dressing is gradually replaced by other dressings.
The biological dressing is improved greatly compared with the traditional dressing, wherein the hydrogel is a hydrophilic reticular polymer swelling body containing a large amount of water, has good water absorption, smooth surface, good biocompatibility, stable composition, low price and weak antigenicity. Hydrogels are widely used in a variety of fields, such as biosensors, drug delivery, and the like.
The living cell-macromolecule grafting method is a mode for constructing engineering bacteria, and is one of important technologies for widening the application advantages of living cells and macromolecules. The modified living cell is endowed with new physicochemical properties, and the complete encapsulation of the living cell is ensured, and the antibacterial performance is strong. The hydrogel constructed by living cells and macromolecules provides a cellular environment similar to a natural cytoplasmic matrix, and provides a very effective bacteriostatic environment for preventing wound infection. In recent years, many researchers report various biomedical applications such as drug release and wound repair by a living cell-polymer grafting method.
Yeast is a unicellular fungus that ferments sugars into alcohol and carbon dioxide, distributed throughout the natural world, and is a typical heterotrophic facultative anaerobic microorganism. Yeast is harmless, grows easily, can survive both aerobic and anaerobic conditions, and is far below the cytotoxic concentration of human cells. The human growth factor as the main active component of the antibacterial material has multiple biological functions, and can be combined with receptors on cell membranes to promote a series of complex biochemical cascade reactions in cells to play a physiological role, promote cell division, and repair skin wounds, gastrointestinal ulcers, corneal injuries and the like.
The invention oxidizes the sugar chain on the surface of the engineering yeast, initiates and polymerizes monomers, and prepares hydrogel through chemical crosslinking of macromolecules. Zero leakage of the yeast is realized, possible immune reaction generated when the yeast is in direct contact with a human body is avoided, and the biocompatibility is good. The yeast cells have strong antagonistic and bacteriostatic abilities, and the possibility of wound infection is reduced.
The human growth factor is expressed in situ on the yeast cell to promote the autolysis of necrotic tissues and the growth of new tissues, and the in situ expression avoids the inactivation of the growth factor in a short-range release mode to keep lasting activity. The hydrogel formed by crosslinking has good stress and stretchability, can reduce the contact between the surface of a wound and the outside, is favorable for the permeation of nutrient substances and the discharge of metabolic waste, and accelerates the healing of the wound. The material with excellent antibacterial property and protein adsorption resistance can be further used in special environments such as diabetic wounds and ulcers. The invention further promotes the development of biological material science and provides a new method for better application of microorganisms.
Disclosure of Invention
The invention aims to overcome the defects of the existing wound dressing, and provides a leak-free packaged yeast hydrogel and a preparation method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a non-leakage encapsulated yeast hydrogel and a preparation method thereof are characterized by comprising the following steps:
(1) Constructing engineering bacteria carrying growth factors yeast: connecting the human cell growth factor gene optimized by the yeast cell codon to a vector to construct a recombinant plasmid carrying the growth factor; introducing the recombinant plasmid carrying the growth factor into yeast competent cells, and screening out engineering bacteria of which the target genes are successfully integrated into a yeast genome; carrying out shake flask fermentation culture on the engineering bacteria to obtain yeast engineering bacteria for expressing growth factors;
(2) Preparation of hydrogel: and (2) carrying out in-situ oxidation on the surface sugar chain of the engineering yeast obtained in the step (1), initiating, and carrying out specific crosslinking on the high molecules to prepare the leakage-free encapsulated yeast hydrogel.
The human cell growth factor gene in the step (1) of the preparation method comprises a human epidermal growth factor hEGF gene and a human vascular endothelial growth factor hVEGF gene; the codon-optimized hEGF gene sequence is shown in SEQ ID NO. 1; the codon optimized hVEGF gene sequence is shown in SEQ ID NO. 2.
The preparation of the hydrogel in the step (2) in the preparation method comprises the following specific steps:
1) Washing bacterial liquid: streaking the engineering yeast flat plate obtained in the step (1), putting the engineering yeast flat plate into an incubator for overnight culture at 30 ℃, picking a single colony on the flat plate by using a gun head, and performing shake amplification culture on 12h by using a liquid culture medium at 30 ℃ and 180 rpm; centrifuging the expanded and cultured bacterial liquid, adding PBS buffer solution for washing, centrifuging for 2 times, and adding 50 mL PBS buffer solution for resuspension to obtain yeast suspension;
2) Surface sugar chain in-situ oxidation: adding an oxidant into the yeast suspension, carrying out ice bath for 30 minutes in a dark place, centrifuging after the reaction is finished, and adding a PBS (phosphate buffer solution) for heavy suspension to obtain an oxidized yeast suspension;
3) And (3) initiation: adding an initiator into the oxidized yeast suspension, fully and uniformly mixing, carrying out a light-shielding reaction at 37 ℃ for 1 h, centrifuging, and adding a PBS buffer solution for heavy suspension to obtain the initiated yeast suspension.
4) Specific crosslinking of macromolecules: adding yeast suspension, a cross-linking agent, cuBr, water, a hydrogel monomer and ascorbic acid which are initiated into a sealed round-bottom bottle, mixing, denitrifying the bottle for 55min, exposing the mixed solution in the air to stop reaction, irradiating by 360nm ultraviolet light, and specifically crosslinking for 30min to obtain transparent and elastic jelly, namely the non-leakage packaged yeast hydrogel.
Further, the concentration of the yeast suspension in step 1) in the above preparation method is: 1X 10 8 one/mL.
Further, in the above preparation method, the oxidizing agent in step 2) is sodium periodate (NaIO) 4 ) The final concentration was 2 mg/ml.
Further, in the step 3) of the above preparation method, the initiator is 2-bromo-2-methylpropanoic acid-2-aminooxyethyl ester (ABM) with a final concentration of 1 mg/ml.
Further, in the above preparation method, the cross-linking agent in step 4) is ethylene glycol dimethacrylate and dimethacrylate, and the hydrogel monomer is any one of methacrylated hyaluronic acid, methacrylated gelatin and methacrylated chitosan.
Further, in step 4) of the above preparation method, 1 mL-initiated yeast suspension, 15 μ L of crosslinking agent ethylene glycol dimethacrylate and 0.2mL dimethacrylate, 6 mg of CuBr, 2mL water, 50 μ L of hydrogel monomer, 0.1 mL ascorbic acid with a concentration of 0.074g/mL were added to a sealed round-bottomed bottle and mixed.
A leak-free encapsulated yeast hydrogel prepared by the method described above.
Use of the above-described leak-free encapsulated yeast hydrogel in a wound dressing.
The invention has the following remarkable advantages:
(1) The method of the invention oxidizes and initiates sugar chains on the surface of the engineering yeast, and the leakage-free encapsulated yeast hydrogel is prepared by the specific mutual crosslinking of high molecular monomers. The non-leakage encapsulated yeast hydrogel can effectively ensure zero leakage of yeast, reduce possible immunoreaction when the non-leakage encapsulated yeast hydrogel is in direct contact with a human body, and is good in biocompatibility and mild in reaction.
(2) The human growth factor on the yeast cell can effectively accelerate the growth of epithelial cells and the healing of wounds, and the human growth factor is used as an active ingredient of the antibacterial material and can keep the activity in a short-range release mode. The method can approximately obtain stable growth factor concentration by only controlling the yeast concentration, and accurately control the drug administration. Therefore, the preparation method has considerable application in the aspects of development of medical dressings, bioactive materials and the like.
Drawings
FIG. 1 shows the WB pattern of hEGF and hEGF-GS 115; wherein Lane1: hEGF; lane2: hEGF-GS115.
FIG. 2 is an image of yeast cells in hEGF-methylpropenylhyaluronic acid (HAMA) hydrogel.
FIG. 3 is a graph showing that yeast cells in hEGF-methylpropenoic hyaluronic acid (HAMA) hydrogel are completely encapsulated without release. 1-6 are culture solutions taken at different times (24 h, 48h, 72h, 96h, 120h and 144 h).
FIG. 4 is a graph of yeast concentration versus hEGF release for hEGF-methyl allenated hyaluronic acid (HAMA) hydrogels.
FIG. 5 is a graph showing the proliferation of yeast cells in hEGF-methylpropenoic hyaluronic acid (HAMA) hydrogel.
FIG. 6 is an inverted view of hEGF-methylpropanoylated hyaluronic acid (HAMA) hydrogel.
FIG. 7 is a graph of the effect of hEGF-methylalkylenehyaluronic acid (HAMA) hydrogel as a wound dressing on wound healing.
Detailed Description
In order to make the present invention more comprehensible, the present invention is further described in conjunction with the embodiments, and the embodiments described herein are only for explaining the related invention and do not limit the invention.
Example 1: construction of hEGF-Methylpropylenehyaluronic acid (HAMA) hydrogel
Construction of yeast engineering bacteria: connecting a yeast cell codon preference optimized human epidermal growth factor (hEGF) gene sequence (SEQ ID NO. 1) to a pGAPZ alpha A vector to construct a recombinant plasmid carrying hEGF; introducing the recombinant plasmid carrying the hEGF into a yeast competent cell GS115, and screening out engineering bacteria of which the hEGF gene is successfully integrated into a yeast genome; the yeast engineering bacteria for expressing the recombinant protein are obtained by adopting shake flask fermentation culture under the conditions of 30 ℃ and 12h and identified by a Western immunoblotting method (Western Blot).
2. Preparing hydrogel:
1) Washing bacterial liquid: and (2) streaking the engineering yeast flat plate obtained in the step (1), and putting the engineering yeast flat plate into an incubator for overnight culture at 30 ℃. Single colonies on the plate were picked up by a tip and subjected to shake-propagation culture at 30 ℃ and 180 rpm in YPD liquid medium to obtain 12 h. Centrifuging the expanded bacterial solution, adding PBS buffer solution for washing, centrifuging for 2 times, adding 50 mL PBS buffer solution for resuspending to obtain the concentration of 1 × 10 8 Yeast suspension per ml;
2) Surface sugar chain in-situ oxidation: adding sodium periodate (NaIO) as oxidant into the yeast suspension obtained in the step (1) 4 ) Solution of sodium periodate (NaIO) 4 ) The final concentration is 2 mg/ml, ice bath is carried out for 30min in dark place, centrifugation is carried out after the reaction is finished, PBS buffer solution is added for heavy suspension, and the concentration is 1 multiplied by 10 8 An oxidized yeast suspension per ml;
3) And (3) initiation: adding initiator 2-bromo-2-methylpropanoic acid-2-aminooxyethyl ester (ABM) into the oxidized yeast suspension to make the final concentration of ABM be 1 mg/mL, fully mixing uniformly, carrying out dark reaction at 37 ℃ for 1 h, centrifuging at 4 ℃ and 5000 rpm for 7 min, then adding 10 mL PBS buffer solution for heavy suspension,to obtain a concentration of 1X 10 8 Individual/ml of yeast suspension elicited.
4) Specific crosslinking of macromolecules: adding 1mL of yeast suspension, 15 mu L of EGDMA, 0.2mL of PEGDMA, 6 mg of CuBr, 2mL water, 50 mu L of methylpropene-based hyaluronic acid (HAMA) and 0.1 mL ascorbic acid (0.074 g/mL) which are initiated into a sealed round-bottomed bottle, exposing the mixed solution in the air to stop reaction after 55min of denitrification in the bottle, irradiating by 360nm ultraviolet light, and specifically crosslinking for 30min to obtain transparent elastic jelly, namely the non-leakage packaged yeast hydrogel.
Identifying the expression condition of the target protein on the engineering bacteria by using Western Blot, wherein the expression condition of Lane1: a band at 12 kDa (6 kDa in 6kDa hEGF) and a band at 26 kDa in GST tag of Lane2 indicate that the hEGF antibody reacts with the hEGF sample to produce antigen-antibody reaction. The successful expression of hEGF in the engineered bacteria is shown in FIG. 1.
The SEM image of the prepared non-leakage encapsulated yeast hydrogel is shown in FIG. 2, and the prepared hydrogel is observed by using an optical microscope to study the state of yeast cells in the hydrogel. Before the hydrogel was prepared, the yeast was stained with rhodamine B. The results in FIG. 2 show that the yeast cells in the hydrogel were clearly observed under a microscope, the single cells were round and intact in cell shape, and the size was about 1 μm, and the yeast cells were observed in a budding state (in a square frame), and it was preliminarily considered that the yeast cells in the hEGF-methylpropenoic hyaluronic acid (HAMA) hydrogel had activity and growth and propagation ability.
Yeast cells in hEGF-methylpropenylhyaluronic acid (HAMA) hydrogel were observed, and the effect of encapsulation of yeast cells by the hydrogel was investigated. The prepared hEGF-methyl propyl hyaluronic acid (HAMA) hydrogel is placed in PBS (phosphate buffer solution) containing 2 g/100ml of glucose for dialysis for 5 h, after the dialysis is finished, the surface water of the gel is wiped by using filter paper in an aseptic environment, the gel is placed in DMEM (DMEM) culture medium containing 5 ml for culture for 6 days, the culture condition is 30 ℃, culture solution is taken out every 24h and is changed, the culture solution taken out at different times (24 h, 48h, 72h, 96h, 120h and 144 h) is coated on the surface of YPD solid culture medium, 36 h is cultured in an incubator at 30 ℃, and the surface is observed to have no obvious colony, and the result is shown in figure 3. FIG. 3 shows that no yeast colonies appear on the surface of the solid medium, and the result shows that the constructed hEGF-methyl propylene hyaluronic acid (HAMA) hydrogel has a good cell encapsulation effect and can encapsulate yeast cells without leakage.
The yeast cell concentration of the hEGF-methyl propyl hyaluronic acid (HAMA) hydrogel is controlled, the release amount of the hEGF in the hydrogel is measured by an ELISA kit, the release curve of the hEGF release amount slowly rises along with the increase of the yeast concentration, and the stable growth factor concentration of the hEGF-methyl propyl hyaluronic acid (HAMA) hydrogel can be approximately obtained by controlling the yeast concentration (see figure 4).
Yeast cells in hEGF-methyl propylated hyaluronic acid (HAMA) hydrogel were observed, and proliferation of yeast cells was examined. Will be enveloped with 1 × 10 8 The hydrogel of each yeast is cultured at 30 deg.C and 240 rpm, and the OD value of bacterial liquid is measured by sampling every 24h at 1 × 10 8 Individual yeasts are controls; the results are shown in FIG. 5. The results in FIG. 5 show that the hydrogel has no significant effect on the proliferation of yeast cells.
Macroscopic observations were made on hEGF-methylpropenoic hyaluronic acid (HAMA) hydrogels. The prepared hydrogel is placed in a transparent glass bottle and inverted, and the hydrogel is in a uniform, colorless and transparent gel shape and has certain viscosity when being seen by naked eyes. See figure 6 for an illustration of the success of the hydrogel preparation.
Example 2: construction of hEGF-Methacryloylated gelatin (GelMA) hydrogels
1. Construction of yeast engineering bacteria: the same as in example 1.
2. Preparing hydrogel:
1) Washing bacterial liquid: and (2) streaking the engineering yeast flat plate obtained in the step (1), and putting the engineering yeast flat plate into an incubator for overnight culture at 30 ℃. Single colonies on the plate were picked up by a tip and subjected to shake-propagation culture at 30 ℃ and 180 rpm in YPD liquid medium to obtain 12 h. Centrifuging the expanded bacterial solution, adding PBS buffer solution for washing, centrifuging for 2 times, adding 50 mL PBS buffer solution for resuspending to obtain the concentration of 1 × 10 8 Yeast suspension per ml;
2) Surface sugar chain in-situ oxidation: adding sodium periodate (NaIO) as oxidant into yeast suspension 4 ) Sodium periodate (NaIO) 4 ) The final concentration of 2 mg/ml is ice-cooled in dark place for 30 minutes, after the reaction is finished, the mixture is centrifuged, and PBS buffer solution is added for heavy suspension to obtain the concentration of 1 multiplied by 10 8 Yeast suspension after oxidation per ml;
3) And (3) initiation: adding initiator 2-bromo-2-methylpropanoic acid-2-aminooxyethyl ester (ABM) into the oxidized yeast suspension to make ABM final concentration 1 mg/mL, mixing well, reacting at 30 deg.C in dark for 1 h, centrifuging at 30 deg.C and 5000 rpm for 7 min, adding 10 mL PBS buffer solution, and resuspending to obtain 1 × 10 yeast suspension 8 Individual/ml of yeast suspension elicited.
4) Specific crosslinking of macromolecules: adding 1mL of yeast suspension, 15 mu L of EGDMA, 0.2mL of PEGDMA, 6 mg of CuBr, 2mL water, 50 mu L of methacrylic gelatin (GelMA) and 0.1 mL ascorbic acid (0.074 g/mL) which are initiated into a sealed round-bottomed bottle, exposing the mixed solution in the air to stop reaction after 55min of bottle denitrification, irradiating by 360nm ultraviolet light, and specifically crosslinking for 30min to obtain a transparent elastic jelly, namely the non-leakage packaged yeast hydrogel.
Example 3: construction of hEGF-Methylpropanated Chitosan (CSMA) hydrogel
1. Construction of yeast engineering bacteria: the same as in example 1.
2. Preparing hydrogel:
1) Washing bacterial liquid: and (2) streaking the engineering yeast flat plate obtained in the step (1), and putting the engineering yeast flat plate into an incubator for overnight culture at 30 ℃. Single colonies on the plate were picked up by a tip and subjected to shake-propagation culture at 30 ℃ and 180 rpm in YPD liquid medium to obtain 12 h. Centrifuging the expanded bacterial solution, adding PBS buffer solution for washing, centrifuging for 2 times, adding 50 mL PBS buffer solution for resuspending to obtain the concentration of 1 × 10 8 Yeast suspension per ml;
2) Surface sugar chain in-situ oxidation: adding sodium periodate (NaIO) as oxidant into yeast suspension 4 ) Sodium periodate (NaIO) 4 ) Light-shielding ice bath 30 with final concentration of 2 mg/mlAfter completion of the reaction, the reaction mixture was centrifuged and resuspended in PBS buffer to a concentration of 1X 10 8 Yeast suspension after oxidation per ml;
3) And (3) initiation: adding initiator 2-bromo-2-methylpropanoic acid-2-aminooxyethyl ester (ABM) into the oxidized yeast suspension to make ABM final concentration 1 mg/mL, mixing well, reacting at 30 deg.C in dark for 1 h, centrifuging at 30 deg.C and 5000 rpm for 7 min, adding 10 mL PBS buffer solution, and resuspending to obtain 1 × 10 yeast suspension 8 Individual/ml of yeast suspension elicited.
4) Specific crosslinking of macromolecules: adding initiated yeast suspension 1mL, 15 mu L of EGDMA, 0.2mL of PEGDMA, 6 mg of CuBr, 2mL water, 50 mu L of methyl propylene chitosan and 0.1 mL ascorbic acid (0.074 g/mL) into a sealed round-bottomed bottle, exposing the mixed solution to the air to stop reaction after 55min of bottle denitrification, and specifically crosslinking for 30min by ultraviolet irradiation of 360nm to obtain a transparent and elastic jelly, namely the non-leakage packaged yeast hydrogel.
EXAMPLE 4 construction of hVEGF-Methylpropylenehyaluronic acid (HAMA) hydrogel
1. Construction of yeast engineering bacteria: connecting a yeast cell codon preference optimized human hVEGF gene sequence (SEQ ID NO. 2) to a pGAPZ alpha A vector to construct a recombinant plasmid carrying hVEGF; introducing the recombinant plasmid carrying the hVEGF into a yeast competent cell GS115, and screening out engineering bacteria of which the hVEGF gene is successfully integrated into a yeast genome; the yeast engineering bacteria for expressing the recombinant protein are obtained by adopting shake flask fermentation culture under the conditions of 30 ℃ and 12h and identified by a Western immunoblotting method (Western Blot).
2. Preparing hydrogel:
1) Washing bacterial liquid: and (2) streaking the engineering yeast flat plate obtained in the step (1), and putting the engineering yeast flat plate into an incubator for overnight culture at 30 ℃. Single colonies on the plate were picked up by a tip and subjected to shake-propagation culture at 30 ℃ and 180 rpm in YPD liquid medium to obtain 12 h. Centrifuging the expanded bacterial solution, adding PBS buffer solution for washing, centrifuging for 2 times, adding 50 mL PBS buffer solution for resuspending to obtain the concentration of 1 × 10 8 Yeast suspension per ml;
2) Surface sugarChain in-situ oxidation: adding sodium periodate (NaIO) as oxidant into yeast suspension 4 ) Sodium periodate (NaIO) 4 ) The final concentration is 2 mg/ml, ice bath is carried out for 30 minutes in a dark place, centrifugation is carried out after the reaction is finished, PBS buffer solution is added for heavy suspension, and the concentration is 1 multiplied by 10 8 Yeast suspension after oxidation per ml;
3) And (3) initiation: adding initiator 2-bromo-2-methylpropanoic acid-2-aminooxyethyl ester (ABM) into the oxidized yeast suspension to make ABM final concentration 1 mg/mL, mixing well, reacting at 30 deg.C in dark for 1 h, centrifuging at 30 deg.C and 5000 rpm for 7 min, adding 10 mL PBS buffer solution, and resuspending to obtain 1 × 10 yeast suspension 8 Individual/ml of yeast suspension elicited.
4) Specific crosslinking of macromolecules: adding 1mL of yeast suspension, 15 mu L of EGDMA, 0.2mL of PEGDMA, 6 mg of CuBr, 2mL water, 50 mu L of methyl propylated hyaluronic acid (HAMA) and 0.1 mL ascorbic acid (0.074 g/mL) which are initiated into a sealed round-bottomed bottle, exposing the mixed solution in the air to stop reaction after 55min of bottle denitrification, irradiating by 360nm ultraviolet light, and specifically crosslinking for 30min to obtain transparent and elastic jelly, namely the non-leakage packaged yeast hydrogel.
EXAMPLE 5 construction of hVEGF-methacrylated gelatin (GelMA) hydrogel
1. Construction of yeast engineering bacteria: the same as in example 4.
2. Preparing hydrogel:
1) Washing bacterial liquid: and (2) streaking the engineering yeast flat plate obtained in the step (1), and putting the engineering yeast flat plate into an incubator for overnight culture at 30 ℃. Single colonies on the plate were picked up by a tip and subjected to shake-propagation culture at 30 ℃ and 180 rpm in YPD liquid medium to obtain 12 h. Centrifuging the expanded bacterial solution, adding PBS buffer solution for washing, centrifuging for 2 times, adding 50 mL PBS buffer solution for resuspending to obtain the concentration of 1 × 10 8 Yeast suspension per ml;
2) Surface sugar chain in-situ oxidation: adding sodium periodate (NaIO) as oxidant into yeast suspension 4 ) Sodium periodate (NaIO) 4 ) The final concentration is 2 mg/ml, ice bath is carried out for 30 minutes in a dark place, centrifugation is carried out after the reaction is finished, PBS buffer solution is added for heavy suspension, and the concentration is obtainedIs 1 × 10 8 Yeast suspension after oxidation per ml;
3) And (3) initiation: adding initiator 2-bromo-2-methylpropanoic acid-2-aminooxyethyl ester (ABM) into the oxidized yeast suspension to make ABM final concentration 1 mg/mL, mixing well, reacting at 30 deg.C in dark for 1 h, centrifuging at 30 deg.C and 5000 rpm for 7 min, adding 10 mL PBS buffer solution, and resuspending to obtain 1 × 10 yeast suspension 8 Individual/ml of yeast suspension elicited.
4) Specific crosslinking of macromolecules: adding 1mL of yeast suspension, 15 mu L of EGDMA, 0.2mL of PEGDMA, 6 mg of CuBr, 2mL water, 50 mu L of methacrylic gelatin (GelMA) and 0.1 mL ascorbic acid (0.074 g/mL) which are initiated into a sealed round-bottomed bottle, exposing the mixed solution in the air to stop reaction after 55min of bottle denitrification, irradiating by 360nm ultraviolet light, and specifically crosslinking for 30min to obtain a transparent elastic jelly, namely the non-leakage packaged yeast hydrogel.
Example 6 construction of hVEGF-Methylpropanoylchitosan (CSMA) hydrogel
1. Construction of yeast engineering bacteria: the same as in example 4.
2. Preparing hydrogel:
1) Washing bacterial liquid: and (2) streaking the engineering yeast flat plate obtained in the step (1), and putting the engineering yeast flat plate into an incubator for overnight culture at 30 ℃. Single colonies on the plate were picked up by a tip and subjected to shake-propagation culture at 30 ℃ and 180 rpm in YPD liquid medium to obtain 12 h. Centrifuging the expanded bacterial solution, adding PBS buffer solution for washing, centrifuging for 2 times, adding 50 mL PBS buffer solution for resuspending to obtain the concentration of 1 × 10 8 Yeast suspension per ml;
2) Surface sugar chain in-situ oxidation: adding sodium periodate (NaIO) as oxidant into yeast suspension 4 ) Sodium periodate (NaIO) 4 ) The final concentration is 2 mg/ml, ice bath is carried out for 30 minutes in a dark place, centrifugation is carried out after the reaction is finished, PBS buffer solution is added for heavy suspension, and the concentration is 1 multiplied by 10 8 Yeast suspension after oxidation per ml;
3) And (3) initiation: adding 2-bromo-2-methylpropanoic acid-2-aminooxyethyl ester (ABM) as initiator into the yeast suspension after oxidation to make ABM final concentration 1 mg/ml, and chargingMixing, reacting at 30 deg.C in dark for 1 h, centrifuging at 30 deg.C and 5000 rpm for 7 min, adding 10 mL PBS buffer solution, and resuspending to obtain 1 × 10 8 Individual/ml of yeast suspension elicited.
4) Specific crosslinking of macromolecules: adding 1mL of yeast suspension, 15 mu L of EGDMA, 0.2mL of PEGDMA, 6 mg of CuBr, 2mL water, 50 mu L of methyl propenyl Chitosan (CSMA) and 0.1 mL ascorbic acid (0.074 g/mL) into a sealed round-bottom bottle, denitrifying the bottle for 55min, exposing the mixed solution in the air to stop reaction, irradiating by 360nm ultraviolet light, and specifically crosslinking for 30min to obtain a transparent and elastic jelly, namely the non-leakage packaged yeast hydrogel.
Application example 1
The non-leakage packaged yeast hydrogel prepared in example 1 was applied as a wound dressing to the wound surface of mice, and the dressing change was performed on days 3, 6, 9, 12 and 15, respectively, and the wound dressing was photographed and observed. The experimental group was drier on the wound surface and scab faster than the control group as shown in fig. 7.
The above description is only a preferred embodiment of the present invention, and all equivalent changes and modifications made in accordance with the claims of the present invention should be covered by the present invention.
SEQUENCE LISTING
<110> Fuzhou university
<120> leak-free encapsulated yeast hydrogel and preparation method thereof
<130> 2
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 848
<212> DNA
<213> SEQ ID NO.1
<400> 1
gaattcatgt ccccaatcct tggttactgg aagatcaagg gtcttgttca gccaaccaga 60
ctgttgttgg agtacctgga agagaagtac gaggaacact tgtacgaacg tgacgaaggt 120
gataagtggc gtaacaagaa gttcgagctg ggtcttgagt tcccaaacct gccttactac 180
attgacggtg acgttaagtt gactcagtcc atggctatca tcaggtacat tgccgacaag 240
cacaacatgc ttggtggttg cccaaaagag cgtgctgaga tttctatgtt ggagggtgct 300
gtcctggaca tcagatacgg tgtttccaga atcgcttact ccaaggactt cgagactctg 360
aaggttgact tcttgtccaa gttgccagag atgctgaaga tgttcgagga cagattgtgc 420
cacaagacct acttgaacgg tgaccatgtt actcacccag acttcatgtt gtacgacgct 480
ttggacgtcg tcttgtacat ggacccaatg tgtttggacg ctttcccaaa gttggtctgc 540
ttcaagaaga gaatcgaggc tatcccacag atcgacaagt acctgaagtc ctccaagtac 600
attgcttggc cattgcaagg ttggcaggct acttttggtg gtggtgatca tcctccaaag 660
aactctgact ctgagtgccc attgtctcac gatggttact gcttgcatga cggtgtctgt 720
atgtacatcg aggctttgga caagtacgcc tgtaactgtg ttgtcggtta catcggtgag 780
agatgccagt acagagattt gaagtggtgg gagttgagac atcatcacca tcaccactaa 840
gcggccgc 848
<210> 2
<211> 1195
<212> DNA
<213> SEQ ID NO.2
<400> 2
gcgcagacag tgctccagcg cgcgcgctcc ccagccctgc ccggcctcgg gccgggagga 60
agagtagctc gccgaggcgc cgaggagagc gggccgcccc acagcccgag ccggagaggg 120
acgcgagccg cgcgccccgg tcgggcctcc gaaaccatga actttctgct gtcttgggtg 180
cattggagcc ttgccttgct gctctacctc caccatgcca agtggtccca ggctgcaccc 240
atggcagaag gaggagggca gaatcatcac gaagtggtga agttcatgga tgtctatcag 300
cgcagctact gccatccaat cgagaccctg gtggacatct tccaggagta ccctgatgag 360
atcgagtaca tcttcaagcc atcctgtgtg cccctgatgc gatgcggggg ctgctgcaat 420
gacgagggcc tggagtgtgt gcccactgag gagtccaaca tcaccatgca gattatgcgg 480
atcaaacctc accaaggcca gcacatagga gagatgagct tcctacagca caacaaatgt 540
gaatgcagac caaagaaaga tagagcaaga caagaaaaaa aatcagttcg aggaaaggga 600
aaggggcaaa aacgaaagcg caagaaatcc cggtataagt cctggagcgt tccctgtggg 660
ccttgctcag agcggagaaa gcatttgttt gtacaagatc cgcagacgtg taaatgttcc 720
tgcaaaaaca cagactcgcg ttgcaaggcg aggcagcttg agttaaacga acgtacttgc 780
agatgtgaca agccgaggcg gtgagccggg caggaggaag gagcctccct cagggtttcg 840
ggaaccagat ctctcaccag gaaagactga tacagaacga tcgatacaga aaccacgctg 900
ccgccaccac accatcacca tcgacagaac agtccttaat ccagaaacct gaaatgaagg 960
aagaggagac tctgcgcaga gcactttggg tccggagggc gagactccgg cggaagcatt 1020
cccgggcggg tgacccagca cggtccctct tggaattgga ttcgccattt tatttttctt 1080
gctgctaaat caccgagccc ggaagattag agagttttat ttctgggatt cctgtagaca 1140
cacccaccca catacataca tttatatata tatatattat atatatataa attaa 1195
Claims (7)
1. A preparation method of a non-leakage encapsulated yeast hydrogel is characterized by comprising the following steps:
(1) Constructing engineering bacteria carrying growth factors yeast: connecting the human cell growth factor gene optimized by the yeast cell codon to a vector to construct a recombinant plasmid carrying the growth factor; introducing the recombinant plasmid carrying the growth factor into yeast competent cells, and screening out engineering bacteria of which the target genes are successfully integrated into a yeast genome; carrying out shake flask fermentation culture on the engineering bacteria to obtain yeast engineering bacteria for expressing growth factors;
(2) Preparation of hydrogel: in-situ oxidation is carried out on sugar chains on the surface of the engineering yeast obtained in the step (1), and induced, and the leakage-free encapsulated yeast hydrogel is prepared by macromolecular specific crosslinking;
the human cell growth factor gene in the step (1) comprises a human epidermal growth factor hEGF gene and a human vascular endothelial growth factor hVEGF gene; the codon-optimized hEGF gene sequence is shown in SEQ ID NO. 1; the codon optimized hVEGF gene sequence is shown in SEQ ID NO. 2;
the preparation of the hydrogel in the step (2) comprises the following specific steps:
1) Washing bacterial liquid: streaking the engineering yeast flat plate obtained in the step (1), putting the engineering yeast flat plate into an incubator for overnight culture at 30 ℃, picking a single colony on the flat plate by using a gun head, and performing shake amplification culture on 12h by using a liquid culture medium at the conditions of 30 ℃ and 180 rpm; centrifuging the expanded and cultured bacterial liquid, adding PBS buffer solution for washing, centrifuging for 2 times, and adding 50 mL PBS buffer solution for resuspension to obtain yeast suspension;
2) Surface sugar chain in-situ oxidation: adding an oxidant into the yeast suspension, carrying out ice bath for 30min in a dark place, centrifuging after the reaction is finished, and adding a PBS (phosphate buffer solution) for heavy suspension to obtain an oxidized yeast suspension; the oxidant is sodium periodate;
3) And (3) initiation: adding an initiator into the oxidized yeast suspension, fully and uniformly mixing, carrying out a light-shielding reaction at 37 ℃ for 1 h, centrifuging, and adding a PBS buffer solution for heavy suspension to obtain an initiated yeast suspension; the initiator is 2-bromo-2-methylpropanoic acid-2-aminooxyethyl ester;
4) Specific crosslinking of macromolecules: adding yeast suspension, a cross-linking agent, cuBr, water, a hydrogel monomer and ascorbic acid which are initiated into a sealed round-bottomed bottle, mixing, denitrifying the bottle for 55min, exposing the mixed solution in the air to stop reaction, irradiating by 360nm ultraviolet light, and specifically crosslinking for 30min to obtain transparent and elastic jelly, namely the non-leakage packaged yeast hydrogel; the cross-linking agent is ethylene glycol dimethacrylate and dimethacrylate, and the hydrogel monomer is any one of methacrylated hyaluronic acid, methacrylated gelatin and methacrylated chitosan.
2. The method of claim 1, wherein: the concentration of the yeast suspension in the step 1) is as follows: 1X 10 8 one/mL.
3. The method of claim 1, wherein: the oxidant sodium periodate in the step 2) has the final concentration of 2 mg/ml.
4. The method of claim 1, wherein: the initiator 2-bromo-2-methylpropanoic acid-2-aminooxyethyl ester in the step 3) has a final concentration of 1 mg/ml.
5. The method of claim 1, wherein: in step 4), 1 mL-initiated yeast suspension, 15. Mu.L of crosslinker ethylene glycol dimethacrylate and 0.2mL dimethacrylate, 6 mg of CuBr, 2mL water, 50. Mu.L of hydrogel monomer, 0.1 mL concentration 0.074g/mL of ascorbic acid were added to the sealed round-bottomed bottle and mixed.
6. A leakless encapsulated yeast hydrogel prepared by the method of any one of claims 1 to 5.
7. Use of the leak-free encapsulated yeast hydrogel of claim 6 in the preparation of a wound dressing.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210103555.3A CN114470312B (en) | 2022-01-28 | 2022-01-28 | Non-leakage packaged yeast hydrogel and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210103555.3A CN114470312B (en) | 2022-01-28 | 2022-01-28 | Non-leakage packaged yeast hydrogel and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114470312A CN114470312A (en) | 2022-05-13 |
CN114470312B true CN114470312B (en) | 2022-12-13 |
Family
ID=81476025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210103555.3A Active CN114470312B (en) | 2022-01-28 | 2022-01-28 | Non-leakage packaged yeast hydrogel and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114470312B (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0611709B2 (en) * | 1984-10-19 | 1994-02-16 | チロン コーポレイション | Composition for the treatment of corneal matrix wounds |
CN101314762B (en) * | 2008-07-03 | 2011-02-02 | 山东大学 | Yeast engineering bacterium for expression recombination of rainbow trout antimicrobial peptide Oncorhyncin II and preparation method thereof |
-
2022
- 2022-01-28 CN CN202210103555.3A patent/CN114470312B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN114470312A (en) | 2022-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gupta et al. | The production and application of hydrogels for wound management: A review | |
Tomić et al. | Smart poly (2-hydroxyethyl methacrylate/itaconic acid) hydrogels for biomedical application | |
CN107118359B (en) | Photo-curing hydrogel and preparation method thereof | |
CN112300420B (en) | Injectable antibacterial interpenetrating double-network hydrogel and preparation method and application thereof | |
CN101534870A (en) | Hydrogel wound dressing and biomaterials formed in situ and their uses | |
WO2017103263A1 (en) | Multi-layered wound care product | |
CN115975224B (en) | pH/ROS double-response tissue adhesion carrier hydrogel and preparation method and application thereof | |
CN108310452A (en) | Temperature-sensitive glucan-based hydrogel and preparation method thereof | |
CN111643720A (en) | Hydrogel with antibacterial property for healing burn wound and preparation method thereof | |
CN112029037A (en) | High-strength degradable antibacterial hydrogel and preparation method thereof | |
CN114470312B (en) | Non-leakage packaged yeast hydrogel and preparation method thereof | |
CN115475283A (en) | Tissue engineering bone constructed based on hydrogel material and preparation method and application thereof | |
CN112007210A (en) | Photoinitiated polyethylene glycol-based hydrogel dressing and preparation method thereof | |
Konur | The pioneering research on the wound care by alginates | |
CN115181226B (en) | Micromolecule silk fibroin-based hydrogel and preparation method and application thereof | |
CN115671368B (en) | Nanofiber composite patch for removing biological membrane and preparation method thereof | |
CN114377194B (en) | Bandage or dressing for preventing and/or treating skin injury and application thereof | |
WO2010067378A2 (en) | Hydrogel composition | |
CN114796582A (en) | Preparation method of bacteriostatic gel containing graphene oxide | |
CN113384743A (en) | Preparation method of temperature-sensitive dressing with tissue repair promoting and antibacterial functions | |
Bhalerao et al. | Hydrogel based drug delivery system: A review | |
CN116712387B (en) | Sugar response hydrogel for promoting healing of diabetic skin wound surface and preparation method thereof | |
CN114949338B (en) | Hydrogel capable of resisting drug-resistant bacteria for long time and preparation method and application thereof | |
CN116889618B (en) | Medicine for treating diabetic skin wound and preparation method thereof | |
KR100372560B1 (en) | Charcoal filled hydrogels dressings and process for preparing thereof by irradiation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |